Form 4: GC Corp. and GC Cell Corp. Report Changes in Ownership of Artiva Biotherapeutics Following IPO

GC Corp. and GC Cell Corp. report changes in beneficial ownership of Artiva Biotherapeutics common stock following the company's initial public offering.

Summary

• GC Corp. and GC Cell Corp. filed a Form 4 with the SEC detailing changes in their beneficial ownership of Artiva Biotherapeutics, Inc. (ARTV) common stock on July 22, 2024.
• The filing reflects transactions related to the conversion of preferred stock and simple agreements for future equity (SAFE) into common stock upon the closing of Artiva's IPO.
• GC Corp. acquired 667,185 shares of common stock through the conversion of Series A Preferred Stock and 330,095 shares through the conversion of Series B Preferred Stock.
• Additionally, GC Corp. acquired 294,117 shares through the conversion of a $3,000,000 SAFE at a 15% discount to the IPO price and purchased 1,666,666 shares in the IPO at $12 per share.
• GC Cell Corporation acquired 292,791 shares through the conversion of Series A Preferred Stock and 62,181 shares through the conversion of Series B Preferred Stock.
• GC Cell Corporation also acquired 256,316 shares through the conversion of a $2,614,424.28 SAFE at a 15% discount to the IPO price and purchased 416,666 shares in the IPO at $12 per share.
• Following these transactions, GC Corp. directly owns 3,306,900 shares of common stock and indirectly owns 1,260,512 shares through GC Cell Corporation.
• GC Cell Corporation directly owns 1,260,512 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard transactions related to the IPO, with GC Corp. and GC Cell Corp. increasing their holdings, indicating confidence in the company.

Positives

• The conversion of preferred stock and SAFEs into common stock indicates confidence in Artiva Biotherapeutics' future prospects.
• The purchase of shares in the IPO by GC Corp. and GC Cell Corporation demonstrates further investment in the company's growth.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.

Stakeholder Impact

• The changes in ownership may influence investor perception of Artiva Biotherapeutics.
• The increased holdings by GC Corp. and GC Cell Corp. could signal long-term confidence in the company's prospects.

Key Dates